Impacts of Cytochrome P450 2D6 (CYP2D6) Genetic Polymorphism in Tamoxifen Therapy for Breast Cancer

Tamoxifen (TMX) is the main drug used both in pre and postmenopausal women as adjuvant treatment for hormone receptor-positive breast cancer. An important barrier to the use of TMX is the development of drug resistance caused by molecular processes related to genetic and epigenetic mechanisms, such...

Descripción completa

Detalles Bibliográficos
Autores principales: Bezerra, Lucas Soares, Santos-Veloso, Marcelo Antônio Oliveira, Bezerra Junior, Natanael da Silva, Fonseca, Lucilia Carvalho da, Sales, Wivianne Lisley Andrade
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Thieme Revinter Publicações Ltda 2018
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10316940/
https://www.ncbi.nlm.nih.gov/pubmed/30536272
http://dx.doi.org/10.1055/s-0038-1676303

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10316940/
https://www.ncbi.nlm.nih.gov/pubmed/30536272
http://dx.doi.org/10.1055/s-0038-1676303

Ejemplares similares